Cholesterol

Cholesterol / 2012 / Article / Tab 1

Clinical Study

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients

Table 1

Lipid-lowering medications in the 9950 coronary artery disease patients.

Lipid-lowering medications Patients

Total number of patients9950
Statin monotherapy5885 (59%)
High potency1692 (17%)
Moderate potency2398 (24%)
Low potency1795 (18%)
Combination 2730 (27%)
Statin plus ezetimibe1378 (14%)
Statin plus niacin866 (9%)
Statin plus fibrate650 (7%)
Statin plus fish oil69 (<1%)
Statin plus bile acid sequestrant43 (<1%)
No statin1335 (13%)
No statin but other lipid lowering 389 (4%)
Ezetimibe179 (2%)
Niacin113 (1%)
Fibrate170 (2%)
Fish oil11 (<1%)
Bile acid sequestrant37 (<1%)
No lipid-lowering therapy946 (10%)

*Among patients on a statin plus another lipid-lowering medication, 276 patients were on more than one non-statin lipid-lowering drug.
Among patients on no statin but another lipid-lowering medication, 121 patients were on more than one non-statin lipid-lowering drug.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.